Italy Neurology Clinical Trials Market Report 2022 to 2030

Italy Neurology Clinical Trials Market Analysis

$ 3999

The Italy Neurology Clinical Trials market is projected to grow from $125.5 Mn in 2022 to $185.5 Mn by 2030, registering a CAGR of 5% during the forecast period of 2022 - 2030. The market will be driven by the rising demand for novel therapies for neurological disorders and the supportive regulatory climate in Italy. The market is segmented by phase, by study design & by indication. Some of the major players include AstraZeneca, Chiesi Farmaceutici & Menarini.

ID: IN10ITCT005 CATEGORY: Clinical Trials GEOGRAPHY: Italy AUTHOR: Vidhi Upadhyay

Buy Now

Italy Neurology Clinical Trials Market Executive Summary

The Italy Neurology Clinical Trials market is projected to grow from $125.5 Mn in 2022 to $185.5 Mn by 2030, registering a CAGR of 5% during the forecast period of 2022 - 2030. Italy has a large and mature pharmaceutical market, with high levels of domestic consumption of both prescription and over-the-counter drugs. There are around 5000 pharmaceutical firms in Italy, including both large and small businesses. Alzheimer's and dementia fatalities in Italy reached 41,445 in 2020, accounting for 7.64% of total deaths, according to the most recent WHO statistics. In 2020, Italy accounted for 3.3% of worldwide clinical trial activity.

The neurology clinical trials landscape in Italy is highly dynamic, with several clinical studies taking place around the nation. Italy has a high frequency of neurological illnesses, including Alzheimer's disease, Parkinson's disease, multiple sclerosis, and epilepsy. As academics and pharmaceutical firms attempt to create novel treatments and cures for these disorders, there has been a surge in interest in neurology clinical trials in Italy. There is a rising interest in discovering novel medicines for neurological illnesses, and several clinical studies are now being conducted to assess the safety and effectiveness of various treatments.

Italy Neurology Clinical Trials Market

Market Dynamics

Market Growth Drivers

The regulatory climate in Italy is largely supportive of clinical trials, with the Italian Medicines Agency (AIFA) in charge of regulating clinical trial permission and conduct in the nation. AIFA has put in place a number of initiatives to help researchers and sponsors through the clinical trial approval procedure. Moreover, Italy has a high frequency of neurological illnesses, including Alzheimer's disease, Parkinson's disease, multiple sclerosis, and epilepsy. It has led to an increasing interest in neurology clinical trials in Italy. Italy additionally has a good research infrastructure, with many international universities, research organizations, and healthcare facilities, as well as a rising demand for novel therapies for neurological disorders, such as gene therapies and stem cell therapies leading to market expansion.

Market Restraints

CNS medicines and injections have a number of adverse effects, including loneliness and difficulty sleeping, raised blood pressure, and nerve damage, which could restrict their usage in the future years. Other factors such as regulatory complexity, insufficient money, and patient recruiting issues hinder the country's clinical trial expansion. Moreover, the COVID-19 pandemic has disrupted clinical studies in Italy, causing delays and interruptions which are yet to be recovered. Italy is likewise competing with other nations for clinical studies. Because of their vast population bases, increased prevalence of neurological disorders, and better healthcare infrastructure and investment, emerging nations such as India, China, and Brazil provide tempting market potential and good competition to Italy’s market expansion.

Competitive Landscape

Key Players

Novartis
Merck & Co.
Biogen
Sanofi
Eli Lilly and Company
AstraZeneca.
Chiesi Farmaceutici (ITA)
Menarini (ITA)
Dompé Farmaceutici (ITA)
Angelini Pharma (ITA)
Recordati (ITA)

Notable Deals

In June 2022, Biogen invested more than $700 million in Alectos' preclinical oral Parkinson's medication to strengthen its pipeline.

Healthcare Policies and Regulatory Landscape & Reimbursement Scenario

The Italian Medicines Agency is the regulatory entity in charge of clinical trials in Italy (AIFA). AIFA is in charge of evaluating, authorising, and monitoring clinical studies in Italy, particularly neurology clinical trials. AIFA guarantees that clinical trials are done in accordance with ethical and legal standards and that participants' safety and rights are maintained.

There are many kinds of financing available in Italy for neurology clinical trials. The Italian government funds research via a variety of entities, including the Ministry of Health, the National Institute of Health (ISS), and the National Research Council (CNR). Moreover, private organisations and charities support clinical trials and research initiatives. Moreover, Italian pharmaceutical and biotech corporations play an important role in supporting neurology clinical studies in Italy. These corporations make significant investments in the research and development of novel medicines and treatments for neurological illnesses, and they often fund clinical studies to evaluate the safety and effectiveness of their medications.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Clinical Trials Regulation in Country
1.6 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Market Size (With Excel and Methodology)
2.2 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation

6. Methodology and Scope

Neurology Clinical Trials Market Segmentation

By Phase (Revenue, USD Billion):

Phase I
Phase II
Phase III
Phase IV

By Study Design Outlook (Revenue, USD Billion):

Epilepsy
Parkinson's Disease (PD)
Huntington's Disease
Stroke
Traumatic Brain Injury (TBI)
Amyotrophic Lateral Sclerosis (ALS)
Muscle regeneration
Others

By Indication Outlook (Revenue, USD Billion):

Interventional
Observational
Expanded Access

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.